JL1025E: Phase 3 multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
Medical Science Liaison Janssen Research & Development
Background: The standard of care for patients with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant chemotherapy and radical cystectomy (RC) or chemoradiotherapy (CRT); however, RC is associated with potential morbidity or mortality from the procedure. TAR-200 is an intravesical drug-delivery system designed for the local continuous release of gemcitabine within the bladder. Cetrelimab is an investigational immunoglobulin G4 anti–programmed cell death protein-1 antibody. In patients with MIBC, this clinical trial will evaluate whether combination treatment with intravesical TAR-200 and systemic cetrelimab will result in enhanced local and systemic antitumor activity versus concurrent CRT.
Methods: SunRISe-2 (NCT04658862) is a prospective, multicenter, open-label, randomized phase 3 study evaluating the efficacy and safety of intravesical TAR-200 plus systemic cetrelimab versus CRT in participants with MIBC. Eligible participants are aged ³18 years with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and histologically proven, cT2-T4a, N0, M0 urothelial carcinoma of the bladder diagnosed within 90 days of the randomization date, and who refuse or are ineligible for RC. Approximately 550 participants will be randomized in a 1:1 ratio and with stratification by 2 factors: transurethral resection of bladder tumor screening results (visibly complete vs incomplete) and screening tumor stage (T0 vs Ta/T1/Tis vs T2-T4a). Participants in Arm 1 will receive intravesical TAR-200 every 3 weeks for the first 18 weeks on study; and, beginning at Week 24, every 12 weeks through study year 3. Cetrelimab will be dosed every 3 weeks until Month 18. Participants in Arm 2 will receive standard-of-care CRT (with either cisplatin or gemcitabine, for up to 6 weeks). A primary disease assessment will be performed at Week 18 to evaluate treatment response in both arms. Subsequent assessments (axial imaging and cystoscopy) will occur at Week 24 and every 12 weeks thereafter through study Year 2, and then every 24 weeks through study Year 5. The primary end point is bladder-intact event-free survival. Key secondary end points include metastasis-free survival, overall survival, overall response rate (at Week 18), and safety and tolerability. Other/exploratory end points include assessments of cancer-specific survival, time to symptomatic progression, pharmacokinetics, immunogenicity, health-related quality of life, healthcare resource utilization, and biomarkers.
Participants are being enrolled at approximately 272 study sites worldwide. The study opened for enrollment in December 2020.
